92 results
8-K
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024. Dr. Rao … annual retainer for his service on the Board and a £6,000 annual retainer for his service as a member of the Research and Development Committee. Further
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
, having joined the company in 2022. He was previously Chief Medical Officer at Oxford Biomedica and Head of Research and Development and Chief Medical
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
, the period during which the results of the trials will become available and our research and development programs;
our estimates regarding expenses
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
............................................... 21 3.2 Research and Development Collaboration Agreement .............................................. 22 4. PRODUCT OPTIONS … with expertise in the research, development, and commercialization of drug products; WHEREAS, pursuant to the terms and conditions of this Agreement, Autolus
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
and our research and development programs;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing … and clinical research and development, and manufacturing and manufacturing process scale-up, and we expect that our ongoing research and development activities
8-K
iiipt fgbmjvzt6c7c
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K/A
EX-99.1
cw2wd
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.2
q7xk74g iak2zz
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
ffvfizpx
14 Mar 24
Results of Operations and Financial Condition
12:32pm
424B5
xgq1i89olglkxe
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
wz0ue is52tn
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
mrtikikeuc9es
7 Feb 24
Automatic shelf registration
10:00pm
10-Q
EX-10.1
o2is 4w0nfwpum0c7buv
9 Nov 23
Quarterly report
4:18pm
10-Q
ab56wrd
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
rxm3j8o
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
3zvhj3om0p2
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
tl5zmr94xme
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
aw73tknxbj97g
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
tqvblhhxh981jfv25d
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.3
oze8gn1
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm